ERBB2 and breast cancer: Maneiro and colleagues demonstrated the specificity of these drugs by creating an antibody–PROTAC conjugate which degraded bromodomain-containing protein 4 (BRD4) specifically in HER2-positive breast cancer cell lines without affecting the BRD4 levels in HER2-negative cells.